Portugal
Menu

Verino® Pro SARS-CoV-2 Ag Rapid Test

COVID-19 Overview

Coronavirus disease 2019 (COVID-19) is of zoonotic origin and caused by the novel beta coronavirus, severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2). People are generally susceptible. Currently, the patients infected by the novel coronavirus are the main source of infection; asymptomatic infected people can also be an infectious source. Based on the current epidemiological investigation, the incubation period is 1 to 14 days, mostly 3 to 7 days. The main manifestations include fever, fatigue and dry cough. Nasal congestion, runny nose, sore throat, myalgia and diarrhea are found in a few cases.
Antigen is generally detectable in upper respiratory specimens during the acute phase of infection. Rapid diagnosis of SARS-CoV-2 infection will help healthcare professionals to treat patients and control the disease more efficiently and effectively.

Product Information

Verino® Pro SARS-CoV-2 Ag Rapid Test is is an in vitro immunochromatographic assay for the rapid, qualitative detection of the nucleocapsid protein antigen from SARS-CoV-2 in human nasal swab, oropharyngeal swab or nasopharyngeal swab specimen.
It is intended to aid in the rapid diagnosis of SARS-CoV-2 infections.

Ordering Information

Catalog Number Description Format Size
56281 Verino PRO SARS-CoV-2 Ag rapid test Cassette 25 tests

Benefits

• Rapid 15 minute testing for SARS-CoV-2 antigen
• Facilitates quick patient treatment decisions
• Simple, time saving procedure
• All necessary reagents provided and no equipment needed
• High sensitivity and specificity

Specification

Time to result 15 minutes
Storage 2-30°C
Shelf life 24 months
Specymen type Nasal swab, Oropharyngeal swab, Nasopharyngeal swab

Contents

• 25 Test cassettes
• 25 Sterile swabs
• 25 Extraction tubes and dropper tips
• 1 Package insert

Performance Characteristics

Verino® Pro SARS-CoV-2 Ag Rapid Test has been evaluated with specimens obtained from patiets. The performance of the tests was compared to a commercialized molecular assay.

Clinical Sensitivity: 97.42%
Clinical Specificity: >99.99%
Clinical Accuracy: 99.32%